Cytostatic therapy
The choice of the dosage regimen is determined by the severity of the emetogenic effect of the antitumor therapy.
For of adults the daily dose, as a rule, is 8-32 mg, the following regimens are recommended:
With moderate emetogenic chemotherapy or radiotherapy:
- 8 mg intravenously struino slowly or intramuscularly, immediately before the start of therapy;
- 8 mg orally 1 to 2 hours before the start of therapy, then another 8 mg orally 12 hours after the start of therapy.
With highly emeticogenic chemotherapy:
- 8 mg intravenously struino slowly just before chemotherapy, and then two further intravenous jet injections of 8 mg, each of which is carried out in 2-4 hours;
- continuous 24-hour infusion of the drug at a dose of 24 mg at a rate of 1 mg / h;
- 16-32 mg, diluted in 50-100 ml of the appropriate infusion solution, in the form of a 15-minute infusion, immediately before the start of chemotherapy.
The efficacy of Lazaran BM can be increased by a single intravenous glucocorticoid (eg, 20 mg dexamethasone) prior to chemotherapy; when ingested to enhance the effect of a single dose can be increased to 24 mg and administered simultaneously with 12 mg of dexamethasone 1-2 hours before the start of chemotherapy.
To prevent delayed (occurring after 24 hours after the initiation of chemotherapy or radiotherapy) vomiting, it is recommended to continue using the drug inside as tablets 8 mg twice a day for 5 days.
Children
Children older than 2 years of the drug is administered at a dose of 5 mg / m2 body surface intravenously, immediately before the start of chemotherapy, followed by oral administration at a dose of 4 mg after 12 hours; after the end of chemotherapy, it is recommended to continue treatment at 4 mg twice daily for 5 days.
Prevention of postoperative nausea and vomiting
Adults inject a single dose of 4 mg intramuscularly or intravenously slowly at the onset of anesthesia, or prescribe 16 mg orally 1 hour prior to the onset of anesthesia.
For relief of nausea and vomiting it is recommended intramuscular or slow intravenous injection of 4 mg of the drug.
Intramuscularly into the same site of the body, Lazaran BM can be administered at a dose not exceeding 4 mg!
Children To prevent postoperative nausea and vomiting, Lazaran BM is used exclusively parenterally at a single dose of 0.1 mg / kg (max. 4 mg) as a slow intravenous injection before or after anesthesia.
To treat the development of postoperative nausea and vomiting in children, a slow intravenous injection of a single dose of the drug 0.1 mg / kg (maximum 4 mg) is recommended.
With regard to the prevention and treatment of postoperative nausea and vomiting in children under 2 years of age there is no sufficient experience.
Elderly patients
Dosage adjustments are not required.
Patients with kidney and liver lesions
With renal damage, the usual daily dose and frequency of administration of the drug is not required.
With liver damage the clearance of Lazaran BM significantly decreases, and the half-life of it is increased from the plasma, therefore, do not exceed the daily dose of 8 mg per day.
To dilute the injection solution, the following solutions can be used:
0.9% solution of sodium chloride,
5% solution, Ringer's solution,
0.3% potassium chloride solution and 0.9% sodium chloride solution,
0.3% potassium chloride solution and 5% dextrose solution.